Antiviral Res LIU Q, Tang B, Xuan X, Wang H, et al The potential of leritrelvir repositioning for the treatment of coxsackievirus B4 and common enterovirus infections. Antiviral Res. 2026 Feb 16:106367. doi: 10.1016/j.antiviral.2026.106367. PubMed Abstract available Emerg Infect Dis KASAI M, Sakuma H, Suzuki M, Nishiyama M, et al Life-Threatening SARS-CoV-2-Associated Encephalopathy and Multiorgan Failure in Children, Asia and Oceania, 2022-2024. Emerg Infect Dis. 2026;32:169-179. PubMed Abstract available Int J Infect Dis MA Q, Yao L, Ding H, Tian W, et al SARS-CoV-2 Variant Specific Protective Immunity and Long-term Immune Recovery in People Living With HIV: A Retrospective Cohort Study. Int J Infect Dis. 2026 Feb 16:108491. doi: 10.1016/j.ijid.2026.108491. PubMed Abstract available J Med Virol EXPRESSION OF CONCERN: Resistance-As...
Antiviral Res WRONSKI S, Obernolte H, Schaudien D, Braun A, et al Prophylactic intranasal administration of bacterial lysate OM-85 mitigates human rhinovirus (RV-A1b) lung infection and inflammation in mice. Antiviral Res. 2026;247:106362. PubMed Abstract available HEDSKOG C, Rodriguez L, Hu Y, Li J, et al SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19. Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351. PubMed Abstract available RODRIGUEZ L, Hu Y, Li J, Han D, et al SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19. Antiviral Res. 2025 Dec 29:106339. doi: 10.1016/j.antiviral.2025.106339. PubMed Abstract available Arch Virol LIM KS, Selvan ME, Ea CK...